A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung (TROG 13.01 SAFRON II)

Overview

The main purpose of this study is to determine the safety (defined as number of participants experiencing ≥ 5% toxicity at 12 months post treatment) of stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung.

Full Title of Study: “Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 27, 2020

Detailed Description

Stereotactic Ablative Body Radiotherapy (SABR) is an exciting novel radiotherapy technique that is delivered over very few sessions. In the case of limited pulmonary 'oligometastases', SABR can result in long-term survival. It is non-invasive and associated with high rates of tumour control and relatively low toxicity. Additionally, the large doses of precision radiotherapy involved may evoke a strong immune response to recognise and attack any remaining tumour cells. In the future, SABR may be an attractive alternative to invasive surgery. There are two SABR techniques emerging in Australia; fractionated and single fraction treatments. We aim to conduct the first clinical trial of SABR in patients with limited pulmonary metastases testing fractionated versus single fraction treatments. The primary aim of this study is to evaluate the toxicity, Quality of Life, clinical efficacy and cost effectiveness of single fraction SABR compared to multi-fraction SABR in patients with oligometastases to the lung. The secondary aim of this study is to assess the immune response evoked by both fractionated and single fraction SABR and its prognostic implications for patient outcomes.

Interventions

  • Radiation: Multi-fraction SABR
    • Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
  • Radiation: Single Fraction SABR
    • Single fraction SABR; 28Gy delivered in 1 fraction

Arms, Groups and Cohorts

  • Experimental: Multi-fraction SABR
    • Radiotherapy: 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
  • Experimental: Single fraction SABR
    • Radiotherapy: 28Gy delivered in 1 fraction

Clinical Trial Outcome Measures

Primary Measures

  • Toxicity
    • Time Frame: 12 months
    • The primary outcome is safety, defined as number of participants experiencing less than or equal to 5% toxicity at 12 months post treatment (toxicity as measured by CTCAE V4).

Secondary Measures

  • Quality of Life
    • Time Frame: 24 months
    • To compare quality of life outcomes between techniques assessed using EQ-5DL and MDASI-LC questionnaires.
  • Time to local failure
    • Time Frame: 24 months
    • Local progression free survival assesed by CT scan and clinical assessment
  • Overall survival
    • Time Frame: 24 months
    • Overall survival assesed by clinical assessment
  • Time to distant failure
    • Time Frame: 24 months
    • Time to distant failure assessed by CT scan and clinical assessment
  • Resources use and costs associated with treatment
    • Time Frame: 24 months
    • Resources use and costs associated with treatment assessed by EQ5DL and accessing Medicare data
  • Disease Free Survival
    • Time Frame: 24 months
    • Disease free survival will be measured from the date of randomisation to the date of a local recurrence, regional or distant metastasis, or death from any cause, whichever occurs first.

Participating in This Clinical Trial

Inclusion Criteria

1. A maximum of three metastases to the lung from any non-haematological malignancy 2. Tumour diameter ≤5cm 3. Targets are located away from central structures (defined as 2cm beyond bifurcation of lobar bronchi and central airways). Targets in proximity to chest wall and mediastinum that meet these inclusion criteria are eligible. 4. Patients must be medically inoperable, technically high risk or have declined surgery. Exclusion Criteria:

1. Previous high-dose thoracic radiotherapy. 2. Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently with treatment. Hormonal manipulation agents are not excluded (e.g. aromatase inhibitors, selective oestrogen receptor modulators, and gonadotrophin releasing hormone receptor modulators) 3. Targeted agents (such as sunitinib and tarceva) within 7 days of commencement of treatment, or concurrently with treatment.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Trans Tasman Radiation Oncology Group
  • Collaborator
    • Australasian Lung Cancer Trials Group
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Shankar Siva, Study Chair, Peter MacCallum Cancer Centre, Australia

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.